TABLE 1.
Selection of HL-60 and derived sublines available from catalogue culture collections
| Collectiona | Name of line | Identifier | Traits, commentsb |
|---|---|---|---|
| ATCC | HL-60 | CCL-240 | Wild-type HL-60 |
| ATCC | Clone 15 HL-60 | CRL-1964 | Undergoes eosinophilic differentiation when treated with butyric acid; established from a clone of HL-60 (ATCC CCL-240) grown at elevated pH (pH 7.6-7.8) for 2 months |
| ATCC | HL-60/MX1 | CRL-2258 | Selected for mitoxantrone resistance from HL-60 (ATCC CCL-240) |
| ATCC | HL-60/MX2 | CRL-2257 | Selected for mitoxantrone resistance from HL-60 (ATCC CCL-240) |
| ECACC | HL-60 | 98070106 | Wild type; 10% spontaneously differentiated; proportion enhanced by polar-planar compounds (e.g., DMSO, butyrate, hypoxanthine, TPA, actinomycin D, retinoic acid) |
| ECACC | Eos-HL-60 | 96100920 | Variant of HL-60 (ECACC 85011431); although capable of reverting to the parental phenotype, maintains a high degree of eosinophil differentiation |
| ECACC | HL60 15-12 | 88120805 | Capable of chemical differentiation towards neutrophils or monocytes and if culture medium becomes acidic |
| ECACC | HL60 Ast.3 | 88120801 | Variant of HL-60 (ECACC 85011431) capable of differentiating into neutrophils by induction with 1.75% DMSO |
| ECACC | HL60 Ast.4 | 88120802 | Variant of HL-60 (ECACC 85011431) where 50 nM TPA results in limited basophilic differentiation and no differentiation towards monocyte lineage |
| ECACC | HL60 M2 | 88120803 | Expansion of subclones of HL-60 with inherent restricted capacity for neutrophil differentiation |
| ECACC | HL60 M4 | 88120804 | Expansion of subclones of HL-60 with inherent restricted capacity for neutrophil differentiation |
| IFO | HL-60 | IFO50022 | Exhibits more rapid growth than the original HL-60 strain, does not respond to DMSO or TPA for differentiation |
| NIHS (JCRB) | HL60(S) | JCRB0163 | Differentiates to neutrophils or macrophages by tumor promoters, vitamin D3, or cytokines |
| NIHS (JCRB) | HL60RG | JCRB0006 | Subline of the HL60 having faster growth rate but reduced differentiation capability |
a
NIHS (JCRB), National Institute of Health Sciences (Japanese Collection of Research Bioresources), distributed through the Health Science Research Resources Bank, Tokyo, Japan; IFO, Institute for Fermentation, Osaka, Japan, distributed through the Health Science Research Resources Bank.
b
TPA, 12-O-tetradecanoyl phorbol-13-acetate.